W.Va. announces $147M opioid settlement with CVS, Walmart


West Virginia Attorney General Patrick Morrisey presents opening arguments on April 4, 2022, the first day of the trial against opioid drug manufacturers, in Charleston, W.Va. A lawsuit filed by the state of West Virginia accusing several drug manufacturers of misrepresenting the risks of their painkilling drugs will go to trial in April 2023, Morrisey said Tuesday, Sept. 20, 2022. (Kenny Kemp/Charleston Gazette-Mail via AP, File)

CHARLESTON, W.Va. (AP) — Walmart and CVS Pharmacy have settled with the state of West Virginia for a combined total of $147 million in a lawsuit over the companies' roles in contributing to the oversupply of prescription drugs that fueled the opioid epidemic in the country's most impacted state, Attorney General Patrick Morrisey announced Tuesday.

Walmart and CVS were two lawsuits that were part of a larger trial that was pushed back to June of next year along with Kroger and Walgreens. Morrisey recently announced a settlement with Rite Aid for up to $30 million to resolve similar litigation.

The lawsuits allege the pharmacies’ contributions to the oversupply of prescription opioids in the state have caused “significant losses through their past and ongoing medical treatment costs, including for minors born addicted to opioids, rehabilitation costs, naloxone costs, medical examiner expenses, self-funded state insurance costs and other forms of losses to address opioid-related afflictions and loss of lives.”

It brings the total settlements by the state in opioid lawsuits to $875 million, including $296 million with manufacturers, $400 million with wholesalers and $177.5 million involving pharmacies.

“These settlements won’t bring back the lives lost from the opioid epidemic, but these and other settlements will hopefully provide significant help to those affected the most by this crisis in our state,” Morrisey said during a news conference. “This development also avoided a costly and lengthy trial and at the end of the day, West Virginia will have the highest per capita settlement results in the nation fighting for our people.”

Walmart agreed to a settlement of just over $65 million and CVS for $82.5 million. Morrisey said the deal with CVS includes a provision that means West Virginia can still receive money from any future national settlements that arise.


The money from all opioid settlements will be distributed throughout the state to abate the opioid crisis.

In August, West Virginia cities and counties reached a $400 million tentative settlement with three major U.S. drug distributors: AmerisourceBergen, Cardinal Health and McKesson. In April, Morrisey announced the state would receive $99 million in a settlement finalized with Johnson & Johnson’s subsidiary Janssen Pharmaceuticals Inc.

Should you invest $1,000 in CVS Health right now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
4.8896 of 5 stars
$149.12+0.8%3.19%9.30Hold$175.86
McKesson (MCK)
4.83 of 5 stars
$527.79+0.6%0.47%23.91Moderate Buy$533.50
Cardinal Health (CAH)
4.2728 of 5 stars
$102.83-5.0%1.94%40.48Moderate Buy$103.07
CVS Health (CVS)
4.9983 of 5 stars
$69.61-0.2%3.82%10.78Moderate Buy$89.44
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

JNJ shares hit a low, trading near $145 at under 14X earnings. With a high dividend yield, it's poised for a rebound.

Search Headlines: